Browsing Tag
CNS drug development
2 posts
FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission?
Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression.
Why did Newron Pharmaceuticals stock rise by nearly 8% and what triggered investor enthusiasm?
Newron Pharmaceuticals stock rallies 7.88% after evenamide schizophrenia trial data and WCBP presentations highlight breakthrough potential. Read what’s next for investors.